The Vanguard Group Discloses Stake in Avadel Pharmaceuticals

The Vanguard Group, Inc. has revealed an opening position disclosure related to Avadel Pharmaceuticals plc in accordance with Rule 8.3 of the Irish Takeover Panel Act, 1997. As of December 23, 2025, Vanguard holds a significant 6.02% interest in Avadel Pharmaceuticals, represented by 5,863,981 ordinary shares valued at US$0.01 each.

The disclosure indicates recent transaction activities, noting the purchase of 2,227 shares and the sale of 540 shares, both priced at 21.54 USD per unit. No cash-settled or stock-settled derivative transactions were reported, and there are no indemnity or option agreements in place related to these securities.

This disclosure is part of the regulatory requirements, ensuring transparency in significant holdings and transactions within companies subject to takeover discussions. The report does not indicate any agreement concerning voting rights or the future acquisition or disposal of relevant securities.